Find an expert

Dr Fernanda Cardoso is a Brazil-born Australian dual-citizen researcher interested in venom peptide-based biodiscovery and therapeutics development. Cardoso was awarded an MSc in Molecular Pharmacology and a PhD with an emphasis in Biochemistry and Immunology and is part of the Institute for Molecular Bioscience, where she develops novel therapies for complex neurological diseases. Cardoso has interdisciplinary training in the fields of neuropharmacology, medicinal chemistry and chemical biology and a strong background in drug discovery, which provides the skills to identify naturally occurring or synthetic bioactive molecules and to study their effects in human physiology with applications in neurologic disorders such as chronic pain, irritable bowel syndrome (IBS), and motor neuron disease (MND). Please see Dr Cardoso’s Grants and Publications list for more details.

Before joining the University of Queensland, Dr Cardoso was part of the Queensland Institute for Medical Research, holding a prestigious CAPES Postdoctoral Fellowship. During this period, Cardoso developed unique high-throughput screen platforms for discovering protein and peptide targets of novel therapies to combat infectious diseases and novel helminth-derived bioactives with anti-inflammatory properties. Please see Dr Cardoso’s Publications list for more details.

Dr Cardoso is currently part of the Centre for Drug Discovery and manages several industry and academic projects studying ion channel modulators derived from natural repertoires, particularly venoms, and developing novel, effective drugs to treat neurological disorders.

Dr Carroll completed his doctorate in Neuroscience at the University of Queensland in 2001. He was awarded an Isaac Walton Killam Memorial Scholarship to pursue postdoctoral studies at the University of Alberta in 2002, before accepting a position as a Lecturer in Human Motor Control at the University of New South Wales in 2003. He joined the School of Human Movement Studies as a Senior Lecturer in July 2007.

Dr Carroll’s research interests lie in the broad field of integrative human physiology. His work spans the fields of exercise science and integrative neuroscience, with a focus on determining how the central nervous system is reorganised as a consequence of motor learning and exercise. He has a specific interest in the area of strength training. Dr Carroll’s research involves the application of electro-physiological techniques such as Transcranial Magnetic Stimulation (TMS), peripheral nerve stimulation, and electromyography (EMG) in experiments involving human subjects. The ultimate purpose of his work is to generate basic knowledge that will lead to the development of exercise protocols that yield maximal benefits for rehabilitation and injury prevention. His work has been funded by the Australian Research Council (ARC) since 2004.

Associate Professor David Cavallucci is an Hepato-pancreatico-biliary surgical oncologist. He is a graduate of the two-year ANZHPBA post-fellowship program in HPB surgery as well as the surgical oncology and abdominal transplantation Fellowship at the University of Toronto.

He has a special interest in minimally invasive pancreatic and liver surgery with a broad experience of laparoscopic surgery and developing robotic surgery. Outside of oncology, he manages benign biliary disease including the laparoscopic management of bile duct stones and the surgical management of acute and chronic pancreatitis.

Having completed a Masters degree in Biostatistics, he has published on the use of Propensity Scores and novel weighting techniques in observational surgical research and is an editor for HPB Journal. He is active in teaching and maintains a strong interest in clinical and translational research. A/Prof Cavallucci is the Past-President of the Australian and New Zealand Hepatic pancreatic and biliary association (ANZHPBA).

Professor Anders Cervin has a longstanding interest in sino-nasal disorders, endoscopic sinus surgery as well as endoscopic anterior skull base surgery. His research interests includes mucociliary function in the upper airways, the role of Nitric Oxide in chronic sinusitis, the use of macrolide antibiotics as a immune modulator in chronic sinusitis and health economic perspectives on sino-nasal disease. Recent research addresses the role of probiotics in airway infection and inflammation. He has authored several book chapters and over 50 peer reviewed articles.

Alternate email address: Daniel.Chambers@health.qld.gov.au

Professor Dan Chambers is a thoracic transplant physician, interstitial lung disease expert, and translational clinician researcher. He is an internationally recognised authority in the fields of lung fibrosis, cell therapy for lung disease and lung transplantation. His research focuses on the mechanisms and treatments for lung fibrosis, silicosis, transplant rejection and post-transplant complications.

Graduating from UQ in 1993 with the William Nathaniel Robertson Medal and a University Medal, Dan’s career has continued to be recognised by being named one of Australia’s top 200 researchers in all fields and the most highly cited in the field of transplantation for the last three years. Dan was the immediate past Director of the International Lung and Heart-Lung Transplant Registry, the first Australian to be appointed to that role. The Registry remains the most important source of evidence to guide the practice of transplantation globally.

Dan is Executive Director of Research at Australia’s’ largest health service, Metro North Hospital and Health, and heads one of the world’s largest clinical trials programs in lung fibrosis. He is Chair of the Pulmonary Fibrosis Australiasian Clinical Trials Network (PACT). His research program, located at UQ Thoracic Research Centre at Prince Charles Hospital, has attracted over $20 million. He has authored over 150 original papers and book chapters. He is a regular reviewer for all the highest ranked journals in respiratory and transplantation medicine and is Deputy Editor of the Journal for Heart and Lung Transplantation, the highest impact journal in the field.

Qualifications

MBBS(Hons1) UQ, 1993

MED University of Birmingham, UK

Dr. Gary Chan is a NHMRC Emerging Leadership Fellow at the National Centre for Youth Substance Use Research. His principal research interest lies in the field of substance misuse prevention and the application of cutting-edge statistical method for longitudinal analysis and causal inference. His recent publications have been focused on polysubstance use (including alcohol, tobacco and cannabis) profiles in adolescent populations, examinations of urban-rural differences in substance use, and the epidemiology of alcohol, tobacco and cannabis use. He collaborates extensively with leading researchers in major national and international institutes, including the University of Washington, Murdoch Children's Research Institute, University of Melbourne, and University College London. He has also served as a consultant at the United Nations Office of Drugs and Crime to improve exisitng methods for monitoring global trends of illicit substance production, trafficking and use. This work has made significant impact on how global data will be collected, and these new data will be used by the United nations and many national governments to inform drug policy decision making. He is a Deputy Statistical and Methodology Editor for the journal Addiction.

Dr. Chan is also a statistical advisor at the School of Psychology, providing statistical advice to academic staff and RHD students. Since 2016, he has also delivered several advanced statistcal workshops at the School on R and statistical modelling.

Dr Kirat Chand is a Research Fellow at the Perinatal Research Centre at The University of Queensland Centre for Clinical Research (UQCCR). His field of expertise include the establishment of synaptic connections, neurodevelopment and cellular changes associated with injury in the neonatal brain. His current work investigates the evolution of brain injury in fetal growth restricted newborns (FGR) with a particular interest in understanding mechanisms to develop better detection and treatment strategies for FGR newborns. FGR is the second leading cause of perinatal morbidity and mortality, with around 32 million babies born FGR globally each year. FGR is commonly caused by placental insufficiency, resulting in an inadequate supply of oxygen and nutrients to the foetus. The brain is particularly vulnerable to FGR conditions and adverse outcomes in these children range from mild learning difficulties, to neurobehavioral issues, and in some cases cerebral palsy. Currently there are no interventions available to protect the FGR brain. Using the pre-clinical pig model of FGR, we are able to examine perturbations to white and grey matter regions of the newborn brain, with the aim of developing appropriate therapeutic strategies to aid this vulnerable population.

Keith is Molecular Virologist and group leader with a dual appointment within the Australian Bioengineering and Nanotechnology Institute and the School of Chemistry and Molecular Biosciences. His research is focused on vaccine development and the understanding of medically and environmentally significant viruses. Keith is one of the inventors of a UQ’s molecular clamp platform and is the co-leader of a program to produce a vaccine for COVID-19 at UQ. Keith has played a leading role in designing and implementing an epidemic response vaccine pipeline which enabled the progression of UQ’s COVID-19 vaccine candidate from sequence information to clinical trial dosing within 6 months.

Keith completed his PhD at the University of Queensland in 2007 on the structure and function of flavivirus NS3 protease. Subsequently, he spent three years (2007-2010) as a post-doctoral researcher at one of Spain’s most respected research institutes, Instituto Salud Carlos III, where I conducted research on the fusion protein of Respiratory Syncytial viurs as a target for conformationally specific neutralizing antibodies. Keith returned to UQ in 2011 and his research has focused on understanding of many medically and environmentally important viruses and bacteria, particularly focussing on Influenza, Respiratory Syncytial virus (RSV), SARS-CoV-2, Koala Retrovirus and Streptococcus pneumoniae.

Associate Professor Fiona Charlson is a NHMRC Research Fellow at the Queensland Centre of Mental Health Research and School of Public Health, University of Queensland. She is a psychiatric epidemiologist and health services researcher with strong experience in addressing some of the most challenging global mental health research questions. Her research utilises a wide range of highly-specialised research skills, from traditional qualitative and quantitative research methods to new and innovative methods aimed at breaking down barriers to progress in the field. She has been a core member of the Mental Disorders and Illicit Drug Use Research Group for the Global Burden of Disease Study since 2009 and is at the leading edge of research into the mental health impacts of climate change and leads the Social and Emotional wellbeing group of UQ’s Climate Change and Health Transdisciplinary Impact Research Network. Her technical expertise is highly sought after and has attracted collaboration requests and funding from a wide range of national and international stakeholders, including; Queensland Health, the World Health Organization, the Institute for Health Metrics and Evaluation (University of Washington), US National Institutes of Health, Alan Flisher Centre for Public Mental Health (University of Cape Town) and various organisations in low- and middle-income countries.

• My academic qualifications include a PhD in Neurosciences, an MSc in Biochemistry and Molecular Biology, and a Bachelor of Medicine.
• I have initiated and managed multiple projects to develop novel therapeutics for neurological disorders, including: 1) Developing a nanoparticle-based siRNA delivery system for the treatment of Huntington’s disease (ARC project; as Postdoctoral Research Fellow). 2) Examining the treatment effects of intravenous immunoglobulin (IVIg) on epilepsy (Advance Queensland Women’s Academic Fund; as Sole Investigator). 2) Examining the effectiveness of three neuroinflammation modulatory agents on traumatic brain injury and epilepsy through randomised controlled preclinical trials (Seed projects sponsored by industry partners: VivaZome Therapeutics, Implicit Bioscience, and Innate Immunotherapeutics; as Co-investigator). 3) Developing treatment strategies to prevent the development of epilepsy after severe traumatic brain injury and identifying medical imaging biomarkers to evaluate the risk of epilepsy post-injury (two U.S. Department of Defense, Congressionally Directed Medical Research Programs; as Co-investigator). 4) Developing exosomal therapy for traumatic brain injury (Cooperative Research Centres Projects (CRC-P) Grant with two research groups from academic institutions and three pharmaceutical companies; as Principal Investigator).

I am a Senior Research Fellow, NHMRC Emerging Leader Fellow, and Group Leader at UQ Frazer Institute. I was awarded my PhD in late 2017 by Biomedicine Discovery Institute, Monash University. Under the UQ Health Research Accelerator (HERA) program, I lead a team to investigate T and B cell responses that profoundly regulate vaccine responses, viral clearance, and anti-tumour immunity.

My research program employs combinatorial methodologies of Biochemistry and Immunology to uncover new molecular mechanisms controlling T-cell-mediated immunity:

1. The action of T cells is required in antibody responses for suppressing viral infection or tumour growth and to confer protection upon vaccination. In particular, follicular helper T (Tfh) cells, a specialised subset of CD4+ T cells, essentially instruct the B cells to produce long-lived antibody protection. The knowledge of Tfh cells has fundamentally enabled vaccine development and therapy design for autoimmune diseases.

2. T-cell-derived cytokines play pivotal roles in both humoral and cellular immunity. Particularly, interleukin-21 (IL-21) is essential for supporting germinal centre (GC) reaction, where the B cell memory and long-lived antibody responses are generated. Besides, IL-21 is also the only known cytokine to maintain the functionalities of CD8+ T cells in the context of chronic infections or cancers by preventing a loss-of-function program termed 'exhaustion'.

This research program has generated multiple cutting-edge discoveries in the field, producing publications as 1st or joint 1st authors in top-tier journals including Nature Immunology, Science Immunology, and Nature Communications.

Dr Kai-Hsiang Chuang received his Ph.D. degree in electrical and biomedical engineering from the National Taiwan University, Taiwan, in 2001. During his graduate study, he developed methods for improving the detection of brain activity using functional magnetic resonance imaging (fMRI). He undertook postdoctoral research at the National Institutes of Health, USA, from 2003 to 2007, where he focused on understanding brain connectivity using novel functional and molecular imaging. He developed manganese-enhanced MRI for high-resolution imaging functional neural pathways in the rodent brain and cerebral blood flow imaging for mapping the resting-state network of the human brain. He joined the Agency for Science Technology and Research (A*STAR), Singapore, in 2008 as the head of MRI Group in the Singapore Bioimaging Consortium (a national research institute). He established the first preclinical imaging facility in Singapore and facilitated research collaboration across academia, clinic and industry. His lab pioneered functional connectivity imaging of the rodent brain to understand the neural basis and function of resting-state brain network, and the development and application of MRI biomarkers for treatment development. In late 2015, he moved to the University of Queensland, Australia, as an Associate Professor with the Queensland Brain Institute and the Centre for Advanced Imaging. His current research focuses on understanding the structure and function of brain network that underlies cognition and behavior, such as learning, memory and dementia. He is developing multimodal techniques, including fMRI, calcium recording, electrophysiology and optogenetic/chemogenetic neuromodulation, to test hypothesis in transgenic mouse models and then translating to humans to improve the diagnosis and intervention of disorders. The imaging and analysis techniques he developed have been widely used in the research community and some in clinical trials. He is serving on the editorial boards of Frontiers in Neuroscience: Brain Imaging Methods, Imaging Neuroscience and Scientific Reports.

Prof. Eric Chung is a certified Fellow of the Royal Australasian College of Surgeons (RACS) and the Urological Society of Australia and New Zealand (USANZ). He is widely recognized as both Australia's leading surgeon and international expert in the field of male sexual, urinary, and reproduction. He has been appointed to numerous executive positions in various national and international organizations such as the Leader for the Male LUTS section and Past Chair of the Andrology section for the Urological Society of Australia and New Zealand (USANZ), Past Secretary-General and Australia's representative for the Asia Pacific Society of Sexual Medicine (APSSM), Chair of the Surgical Committee and Member-at-Large at the International Society of Sexual Medicine (to name a few) as well as invited to serve on both the International Consultation on Sexual Medicine and International Consultation on Incontinence, both respective peak authority body in all matters in sexual medicine and urinary dysfunction.

Apart from being a full Professorship title holder at the University of Queensland, Prof. Chung has been appointed Associate Professor of Surgery at Macquarie University Hospital and has a Visiting Professorship at the Hong Kong University- Shenzhen Hospital. He has a public appointment as a consultant urological surgeon in the Princess Alexandra Hospital in charge of the urinary reconstructive and prosthetic urology program and serves as an Advisor on the Panel of Clinical Experts for the Australian Government Department of Health. He is the first urologist in Australia to complete an Andrology Fellowship accredited by the Sexual Medicine Society of North America (SMSNA) in 2010. Andrology is a study of Men’s Health, relating to male urinary, sexual and reproductive functions. He also received formal fellowship training in Urinary Reconstructive and Prosthesis Surgery in 2009 from Dr Ross Cartmill OAM who is regarded as the father of modern urologic prosthesis in Australia.

He has a strong subspecialty interest in urological reconstructive and prosthetic surgery and runs an active clinical trial unit in Australia. He has published more than 200 peer-reviewed papers and book chapters, is a regular speaker at major international meetings, and is a surgeon mentor for many surgeons worldwide.

Julie Cichero, PhD is a clinician (SLP), researcher and research professional with more than 25 years clinical and research experience into eating, drinking and swallowing problems (dysphagia). She has made significant contributions to the evidence base for standardised terminology for texture modified food and thick liquids, diagnostic use of swallow-respiratory sounds, characterisation of thick fluids and complexities associated with medication management in dysphagia. Recognised nationally and internationally, Julie is a consultant to professional societies, government organisations, academia, boards and healthcare organisations. As Foundation Co-Chair of IDDSI (Global) for a decade, Julie co-led development of the IDDSI Framework, an initiative to reduce food-related choking risk in vulnerable populations. The IDDSI Framework is used in more than 50 countries around the world.

Professor David A Clark

Royal Brisbane and Women’s Hospital, and University of Queensland, Australia

Prof Clark is a visiting colorectal surgeon at the Royal Brisbane and Women’s Hospital. He qualified from the University of QLD in 1991, trained in surgery in Brisbane, and undertook colorectal fellowships in the United Kingdom. He was admitted as a Fellow of the Royal College of Surgeons at Edinburgh in January 2002.

He is a Professor for the University of QLD and runs a busy clinical practice at the St Vincent's Private Hospital Northside. He has a strong interest in inflammatory bowel disease and the IBD Unit at the RBWH has an active academic program. Prof Clark has presented internationally in the field of IBD and minimally invasive colorectal surgery.

The colorectal unit based at the RBWH has a commitment to education and runs a regular laparoscopic colorectal training course and now supports 3 colorectal fellows and a research co-ordinator. He is a board member of the ANZ Training Board in Colorectal Surgery (ANZTBCRS) and the recent convenor for the Society and Section scientific meetings.

Prof Clark heads the Brisbane Colorectal Reseacrh Unit (CRU) and completed a PhD at the University of Sydney in June 2022. He concurrently supervised 4 PhD candidates through UQ. He is widely published in the fields of minimally invasive surgery and inflammaory bowel disease.

Brisbane is renowned for minimally invasive colorectal surgery and training and teaching are a passion.

Dr Clark is a Senior Lecturer at the School of Biomedical Sciences where he is Head of the Peptide Chemical Biology Lab. He completed his PhD in 2000 at the UQ Chemistry Department studying marine natural products chemistry and chemical ecology with Prof. Mary Garson. He then shifted his research focus towards peptide chemistry, structural biology and drug design when he was recruited to the lab of Prof. David Craik at the IMB. His current research focus is the development of technologies to stabilise peptide therapeutics and the elucidation of the structure/function activity of bioactive peptides.

An ecologist by training – I hold a B.Sc. (Hons) in Marine Ecology from the University of North Carolina, Wilmington and a Ph.D. in Ecological Modelling from Griffith University. I am broadly interested in exploring new ways to (1) understand how natural communities are formed and (2) predict how they will change over time. As an Amplify Fellow at UQ, my current research focuses on developing computational tools and adapting techniques from epidemiology and statistical forecasting to study how organisms and ecosystems respond to environmental change. This work is being applied to investigate natural dynamics for a range of natural systems including host-parasite interactions, wildlife populations and veterinary diseases.

I am an active member of the R community and have written and/or maintain several popular R packages. For example, I’m a lead developer on the MRFcov package for multivariate conditional random fields analyses. I also wrote the mvgam R package for fitting dynamic Generalised Additive Models to analyse and forecast multivariate ecological time series, and I regularly provide training seminars and workshops to help researchers learn techniques in ecological data analysis.

I am currently seeking Honours and PhD candidates with interests and/or skills in veterinary epidemiology, spatial / spatiotemporal modeling and quantitative ecology.

Paul Clarke is Director of the Frazer Institute, a leading translational medical research centre studying cancer, autoimmune diseases, infection and immunity, and the genetic basis of disease. Professor Clarke became Director in 2017 and was previously Associate Dean (Research) in Medicine at the University of Dundee in Scotland, Senior Research Fellow at the University of Manchester in England, and Research Fellow at the European Molecular Biology Laboratory in Heidelberg, Germany. Professor Clarke studied Biochemistry at the University of Bristol and undertook research for his PhD at the University of Dundee.

Frazer Institute, formerly UQ Diamantina Institute, is named in honour of its Founding Director, Emeritus Professor Ian Frazer, co-discoverer of the Gardasil HPV cervical cancer vaccine. Frazer Institute is part of The University of Queensland Faculty of Medicine and is a key partner in the Translational Research Institute, a $360 million research facility at the Princess Alexandra Hospital precinct in Woolloongabba. Scientists and clinical researchers at Frazer Institute develop new methods for the prevention, detection and treatment of human diseases.